{{Rsnum
|rsid=2284220
|Gene=CRHR2
|Chromosome=7
|position=30678487
|Orientation=plus
|GMAF=0.225
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CRHR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 78.1 | 18.8 | 3.1
| HCB | 29.5 | 52.3 | 18.2
| JPT | 36.4 | 43.2 | 20.5
| YRI | 69.8 | 30.2 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 29.5 | 52.3 | 18.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2284220
|Name_s=
|Gene_s=CRHR2
|Feature=Intron
|Evidence=PubMed ID:18408560
|Annotation=This variant in the corticotropin-releasing hormone receptor-2 gene was associated with acute bronchodilator response in the 427-participant Sepracor study, but not in the 608-participant Childhood Asthma Management Program (CAMP) or the 152-participant LODO trial. The mean ages of the participants in the CAMP, Sepracor, and Lodo cohorts were 8.9, 32.6, and 42.9 years of age, respectively. Only Caucasians were analyzed in each of these studies.
|Drugs=salbutamol
|Drug Classes=SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA161614217
}}

{{PMID Auto
|PMID=18617639
|Title=ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2284220
|overall_frequency_n=101
|overall_frequency_d=124
|overall_frequency=0.814516
|n_genomes=50
|n_genomes_annotated=0
|n_haplomes=89
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}